This company listing is no longer active
Oncodesign Société Anonyme Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
24.8%
Tasa de crecimiento de los beneficios
59.4%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 30.8% |
| Tasa de crecimiento de los ingresos | 9.6% |
| Rentabilidad financiera | -54.7% |
| Margen neto | -18.9% |
| Última actualización de beneficios | 30 Jun 2022 |
Actualizaciones de resultados anteriores recientes
Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Oncodesign Société Anonyme. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 22 | 33 | -6 | 19 | 0 |
| 31 Mar 22 | 32 | -3 | 19 | 0 |
| 31 Dec 21 | 32 | 0 | 19 | 0 |
| 30 Sep 21 | 33 | 1 | 18 | 0 |
| 30 Jun 21 | 38 | 2 | 18 | 0 |
| 31 Mar 21 | 38 | 2 | 18 | 0 |
| 31 Dec 20 | 34 | 2 | 18 | 0 |
| 30 Sep 20 | 36 | 2 | 18 | 0 |
| 30 Jun 20 | 38 | 1 | 18 | 0 |
| 31 Mar 20 | 38 | 1 | 18 | 0 |
| 31 Dec 19 | 39 | 2 | 18 | 0 |
| 30 Sep 19 | 36 | 1 | 18 | 0 |
| 30 Jun 19 | 34 | 1 | 18 | 0 |
| 31 Mar 19 | 31 | -1 | 17 | 0 |
| 31 Dec 18 | 28 | -3 | 17 | 0 |
| 30 Sep 18 | 25 | -5 | 16 | 0 |
| 30 Jun 18 | 24 | -7 | 15 | 0 |
| 31 Mar 18 | 23 | -6 | 14 | 0 |
| 31 Dec 17 | 22 | -5 | 13 | 0 |
| 30 Sep 17 | 23 | -2 | 11 | 0 |
| 30 Jun 17 | 18 | 1 | 10 | 0 |
| 31 Mar 17 | 15 | 1 | 8 | 0 |
| 31 Dec 16 | 15 | 1 | 7 | 0 |
| 30 Sep 16 | 14 | 0 | 7 | 0 |
| 30 Jun 16 | 14 | 0 | 6 | 0 |
| 31 Mar 16 | 15 | 1 | 6 | 0 |
| 31 Dec 15 | 15 | 1 | 6 | 0 |
Ingresos de calidad: ALONC is currently unprofitable.
Margen de beneficios creciente: ALONC is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: ALONC is unprofitable, but has reduced losses over the past 5 years at a rate of 24.8% per year.
Acelerando crecimiento: Unable to compare ALONC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: ALONC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.1%).
Rentabilidad financiera
Alta ROE: ALONC has a negative Return on Equity (-54.7%), as it is currently unprofitable.